+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
GLENMARK

Glenmark Pharmaceuticals Share Price

₹2,226.50 -0.2 (-0.01%)

19 Oct, 2026 12:08 PM (IST)

Glenmark Pharmaceuticals live price: ₹2,226.50. It opened at ₹2,230 vs previous close ₹2,227; intraday high/low: ₹2,270/₹2,213. The 50 & 200 DMA stand at ₹2,331.80/₹2,209.50.

Glenmark Pharmaceuticals Performance

  • Today's Low
  • ₹2,213
  • Today's High
  • ₹2,270
  • 52 Week Low
  • ₹1,793
  • 52 Week High
  • ₹2,538
  • Open Price₹2,230
  • Previous Close₹2,227
  • Volume126,628
  • 50 DMA₹2,331.80
  • 100 DMA₹2,300.20
  • 200 DMA₹2,209.50

Glenmark Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -9.03%
  • Over 3 Month -0.4%
  • Over 6 Month -1.02%
  • Over 1 Year + 19.58%

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Invest Now

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 62,837
  • P/B Ratio
  • 5.7
  • Average True Range
  • 62.1
  • EPS
  • 63.7
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -41
  • RSI
  • 39.11
  • MFI
  • 30.11

Latest Stock News Updates

3 bullish stocks to track: Glenmark Pharma, Karur Vysya Bank and Go Digit

Choice Broking analyst Sachin Gupta has recommended three stocks to buy today in cash: Glenmark Pharma, Go Digit and Karur Vysya Bank.

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)

Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window

Intimation for closure of trading window for second quarter of FY 2026-27

Glenmark Pharmaceuticals Financials

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹2,226.50
-0.2 (-0.01%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹2,311.00
  • 50 Day
  • ₹2,331.80
  • 100 Day
  • ₹2,300.20
  • 200 Day
  • ₹2,209.50

Resistance and Support

2236.47 Pivot Speed
  • R3 2,297.70
  • R2 2,282.30
  • R1 2,254.50
  • S1 2,211.30
  • S2 2,195.90
  • S3 2,168.10

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-31 Quarterly Results
2026-05-29 Audited Results & Final Dividend
2026-01-30 Quarterly Results
2025-11-14 Quarterly Results
2025-09-26 Interim Dividend
Date Purpose Remarks
2026-08-31 FINAL Rs.2.50 per share(250%)Final Dividend
2025-10-03 INTERIM Rs.2.50 per share(250%)Interim Dividend
2025-09-15 FINAL Rs.2.50 per share(250%)Final Dividend
View Glenmark Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2003-10-31 Split Stock Split From Rs 10/- per share to Rs 2/-

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
20.89%
16.76%
13.81%
1.88%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products. The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities a View More
  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • ISIN
  • INE935A01035

Similar Stocks to Glenmark Pharmaceuticals

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹2,226 As on 19 October, 2026 | 11:54

The Market Cap of Glenmark Pharmaceuticals is ₹62837.3 Cr As on 19 October, 2026 | 11:54

The P/E ratio of Glenmark Pharmaceuticals is 35 As on 19 October, 2026 | 11:54

The PB ratio of Glenmark Pharmaceuticals is 5.7 As on 19 October, 2026 | 11:54

The 52 week High & Low of Glenmark Pharmaceuticals is ₹2537.6/₹1792.6 respectively As on 19 October, 2026 | 11:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23